Brugada Syndrome

Back

Practice Essentials

Brugada syndrome is a disorder characterized by sudden death associated with one of several ECG patterns characterized by incomplete right bundle-branch block and ST-segment elevations in the anterior precordial leads. See the image below.



View Image

Three types of ST-segment elevation in Brugada syndrome, as shown in the precordial leads on ECG in the same patient at different times. Left panel sh....

Signs and symptoms

Signs and symptoms in patients with Brugada syndrome may include the following:

The lack of a prodrome has been reported to be more common in patients with ventricular fibrillation documented as the cause of syncope in patients with Brugada syndrome.[2]

See Clinical Presentation for more detail.

Diagnosis

Most patients with Brugada syndrome have a normal physical examination. However, such an examination is necessary to exclude other potential cardiac causes of syncope or cardiac arrest in an otherwise healthy patient (eg, heart murmurs from hypertrophic cardiomyopathy or from a valvular or septal defect).

Testing

In patients with suspected Brugada syndrome, consider the following studies:

Laboratory tests that may aid in the diagnosis of Brugada syndrome include the following:

Further testing may be indicated to exclude other diagnostic possibilities.

Imaging studies

Perform echocardiography and/or MRI, primarily to exclude arrhythmogenic right ventricular cardiomyopathy, as well as to assess for other potential causes of arrhythmias.

See Workup for more detail.

Management

To date, the only treatment that has proven effective in treating ventricular tachycardia and fibrillation and preventing sudden death in patients with Brugada syndrome is implantation of an automatic implantable cardiac defibrillator (ICD).

No pharmacologic therapy has been proven to reduce the occurrence of ventricular arrhythmias or sudden death; however, theoretically, drugs that counteract the ionic current imbalance in Brugada syndrome could be used to treat it. For example, quinidine, which blocks the calcium-independent transient outward potassium current (Ito), has been shown to normalize the ECG pattern in patients with Brugada syndrome.[3] However, quinidine also blocks sodium (Na) currents, which could have contrary effects.

See Treatment and Medication for more detail.

Background

Brugada syndrome is a disorder characterized by sudden death associated with one of several electrocardiographic (ECG) patterns characterized by incomplete right bundle-branch block and ST elevations in the anterior precordial leads. See the image below.



View Image

Three types of ST-segment elevation in Brugada syndrome, as shown in the precordial leads on ECG in the same patient at different times. Left panel sh....

In the initial description of Brugada syndrome, the heart was reported to be structurally normal, but this concept has been challenged.[4] Subtle structural abnormalities in the right ventricular outflow tract have been reported.

Brugada syndrome is genetically determined and has an autosomal dominant pattern of transmission in about 50% of familial cases (see Etiology). The typical patient with Brugada syndrome is young, male, and otherwise healthy, with normal general medical and cardiovascular physical examinations.

Patients with Brugada syndrome are prone to develop ventricular tachyarrhythmias that may lead to syncope, cardiac arrest, or sudden cardiac death.[5, 6, 7] Infrahisian conduction delay and atrial fibrillation may also be manifestations of the syndrome.[8, 9]

About 5% of survivors of cardiac arrest have no clinically identified cardiac abnormality. About half of these cases are thought to be due to Brugada syndrome.[10]

At present, implantation of an automatic implantable cardiac defibrillator (ICD) is the only treatment proven effective in treating ventricular tachycardia and fibrillation and preventing sudden death in patients with Brugada syndrome (see Treatment).

Pathophysiology

Brugada syndrome is an example of a channelopathy, a disease caused by an alteration in the transmembrane ion currents that together constitute the cardiac action potential. Specifically, in 10-30% of cases, mutations in the SCN5A gene, which encodes the cardiac voltage-gated sodium channel Nav 1.5, have been found. These loss-of-function mutations reduce the sodium current (INa) available during the phases 0 (upstroke) and 1 (early repolarization) of the cardiac action potential.

This decrease in INa is thought to affect the right ventricular endocardium differently from the epicardium. Thus, it underlies both the Brugada ECG pattern and the clinical manifestations of the Brugada syndrome.

The exact mechanisms underlying the ECG alterations and arrhythmogenesis in Brugada syndrome are disputed.[11] The repolarization-defect theory is based on the fact that right ventricular epicardial cells display a more prominent notch in the action potential than endocardial cells. This is thought to be due to an increased contribution of the transient outward current (Ito) to the action potential waveform in that tissue.

A decrease in INa accentuates this difference, causing a voltage gradient during repolarization and the characteristic ST elevations on ECG. Research has provided human evidence for a repolarization gradient in patients with Brugada syndrome using simultaneous endocardial and epicardial unipolar recordings.[12] See the image below.



View Image

Schematics show the 3 types of action potentials in the right ventricle: endocardial (End), mid myocardial (M), and epicardial (Epi). A, Normal situat....

When the usual relative durations of repolarization are not altered, the T wave remains upright, causing a saddleback ECG pattern (type 2 or 3). When the alteration in repolarization is sufficient to cause a reversal of the normal gradient of repolarization, the T wave inverts, and the coved (type 1) ECG pattern is seen. In a similar way, a heterogeneous alteration in cardiac repolarization may predispose to the development of reentrant arrhythmias, termed phase 2 reentry, that can clinically cause ventricular tachycardia and ventricular fibrillation.[13]

An alternative hypothesis, the depolarization/conduction disorder model, proposes that the typical Brugada ECG findings can be explained by slow conduction and activation delays in the right ventricle (in particular in the right ventricular outflow tract).[11]

One study used ajmaline provocation to elicit a type 1 Brugada ECG pattern in 91 patients, and found that the repolarization abnormalities were concordant with the depolarization abnormalities and appeared to be secondary to the depolarization changes.[14] Using vectorcardiograms and body surface potential maps, investigators were able to show that depolarization abnormalities and conduction delay mapped to the right ventricle.

Etiology

The prototypical case of Brugada syndrome has been associated with alterations in the SCN5A gene, of which nearly 300 mutations have been described.[15] Mutations in other genes have been proposed to cause a variant of Brugada syndrome, including the genes coding for alpha1- and beta2b-subunits of the L-type calcium channel (CACNA1C and CACNB2), which are thought to cause a syndrome of precordial ST elevation, sudden death, and short QT interval.[16]

Mutations in the genes GPD1-L[17] and SCN1B[18] have been identified in a few familial cases. Cases in which a mutation in the SCN5A gene cannot be demonstrated may be due to mutations of these genes, due to other unidentified genes, or located in regions of the coding sequence or promoter region of SCN5A that are not routinely sequenced in lab tests.

Many clinical situations have been reported to unmask or exacerbate the ECG pattern of Brugada syndrome. Examples are a febrile state, hyperkalemia, hypokalemia, hypercalcemia, alcohol or cocaine intoxication, and the use of certain medications, including sodium channel blockers, vagotonic agents, alpha-adrenergic agonists, beta-adrenergic blockers, heterocyclic antidepressants, and a combination of glucose and insulin.[13]

Epidemiology

United States statistics

Because of its recent identification, the prevalence of Brugada syndrome is not well established. In a large university hospital on the West Coast of the United States, the prevalence of a Brugada ECG pattern among unselected, mainly white and Hispanic adults was 2 of 1348 patients (0.14%); in both cases, the ECG patterns were type 2.[19] The prevalence in Asian and other ethnic populations may be higher.

International statistics

In parts of Asia (eg, the Philippines, Thailand, Japan), Brugada syndrome seems to be the most common cause of natural death in men younger than 50 years. It is known as Lai Tai (Thailand), Bangungot (Philippines), and Pokkuri (Japan). In Northeast Thailand, the mortality rate from Lai Tai is approximately 30 cases per 100,000 population per year.[20]

Race-, sex-, and age-related demographics

Brugada syndrome is most common in people from Asia. The reason for this observation is not yet fully understood but may be due to an Asian-specific sequence in the promoter region of SCN5A.[21]

Brugada syndrome is 8-10 times more prevalent in men than in women, although the probability of having a mutated gene does not differ by sex. The penetrance of the mutation therefore appears to be much higher in men than in women.

Brugada syndrome most commonly affects otherwise healthy men aged 30-50 years, but affected patients aged 0-84 years have been reported. The mean age of patients who die suddenly is 41 years.[13]

Prognosis

Brugada syndrome is a cause of polymorphic ventricular tachycardia, which may degenerate into ventricular fibrillation and cause cardiac arrest. Prolonged hypoxia during cardiac arrest may leave patients with neurologic sequelae. Implantable cardioverters-defibrillators (ICDs) are often used to treat patients with Brugada syndrome, exposing them to complications related to device implantation and the potential for inappropriate shocks.

During a mean follow-up of 24 months, sudden cardiac death or ventricular fibrillation occurred in 8.2% of patients with Brugada syndrome. A history of syncope, a spontaneously abnormal ECG, and inducibility during programmed electrical stimulation (by one study) significantly increased this risk.[6]

Brugada syndrome may be a significant cause of death, aside from accidents, in men under 40. The true incidence is not known due to reporting biases. Although there is a strong population dependence, an estimated 4% of all sudden deaths and at least 20% of sudden deaths in patients with structurally normal hearts are due to the syndrome. Those with the syndrome have a mean age of sudden death of 41 ±15 years.[22]

Patient Education

Educating the patient and his or her family members and coworkers about basic cardiopulmonary resuscitation (CPR) is important. Genetic counseling is reasonable if desired by the patient and family.

History

Syncope and cardiac arrest are the most common clinical manifestations leading to the diagnosis of Brugada syndrome. Nightmares or thrashing at night may occur. However, some patients remain asymptomatic, and the diagnosis of Brugada syndrome is suggested by a routine electrocardiogram (ECG) showing ST-segment elevation in leads V1 through V3.

A family history of sudden cardiac death is common, though not universal, as the syndrome can occur sporadically. In about 20% of patients, atrial fibrillation is an associated arrhythmia.[1]

The context of the cardiac event is important. In many cases, cardiac arrest occurs during sleep or rest. Cases occurring during physical activity are rare. Fever is often reported to trigger or exacerbate the clinical manifestations of Brugada syndrome.

A 2012 study suggested that the quality of symptoms prior to syncope can predict a benign or malignant cause in patients with Brugada syndrome. Specifically, the lack of a prodrome was more common in patients with ventricular fibrillation documented as the cause of syncope.[2]

Physical Examination

The physical examination is usually normal in patients with Brugada syndrome. Nevertheless, physical examination is required to rule out other possible cardiac causes of syncope or cardiac arrest in an otherwise healthy patient (eg, heart murmurs from hypertrophic cardiomyopathy or from a valvular or septal defect).

Approach Considerations

Many patients with Brugada syndrome are young and otherwise healthy and may present with syncope. Patients with syncope should not be assumed to have a benign condition, and a 12-lead ECG should be performed.

A drug challenge with a sodium channel blocker should be considered in patients with syncope in whom no obvious cause is found. An experienced physician should interpret the ECGs, and an electrophysiologist should review them if possible.

Further testing may be indicated to exclude other diagnostic possibilities.

Laboratory Studies

Check serum potassium and calcium levels in patients presenting with ST-segment elevation in the right precordial leads. Both hypercalcemia and hyperkalemia may generate an ECG pattern similar to that of Brugada syndrome.

Laboratory markers, such as creatine kinase-MB (CK-MB) and troponin, should be checked in patients who have symptoms compatible with an acute coronary syndrome. Elevations indicate cardiac injury.

Genetic Testing

Patients with high likelihood of Brugada syndrome may be genetically tested for a mutation in SCN5A, which codes for the alpha subunit Nav 1.5 of the cardiac sodium channel. The results of this test support the clinical diagnosis and are important for the early identification of family members at potential risk. However, the yield of genetic testing remains relatively low at this time, with mutations in SCN5A found in only 11-28% of index cases.[15]

Echocardiography and MRI

Echocardiography and/or MRI should be performed, mainly to exclude arrhythmogenic right ventricular cardiomyopathy. However, these studies are also used to assess for other potential causes of arrhythmias, such as hypertrophic cardiomyopathy, unsuspected myocardial injury, myocarditis, or aberrant coronary origins.

Electrocardiography

Three ECG patterns have been described in Brugada syndrome[23] (see the image and table below). Placing the right precordial leads in the second intercostal space has been proposed to add sensitivity to the ECG diagnosis of Brugada syndrome.[24] Exercise stress testing may suppress ECG changes and arrhythmias.



View Image

Three types of ST-segment elevation in Brugada syndrome, as shown in the precordial leads on ECG in the same patient at different times. Left panel sh....

Table. ECG Patterns in Brugada Syndrome



View Table

See Table

Recently, the QRS duration on 12-lead ECG has been suggested as a risk marker for vulnerability to dangerous arrhythmias.[25, 26] Inferolateral repolarization abnormalities have also been proposed to be a marker of risk.[27, 28]

Asymptomatic patients with a type 1 ECG pattern on routine ECG represent a difficult case. According to the latest consensus guidelines, a clinical electrophysiologist should evaluate patients in this situation.[13] Patients should be risk-stratified using the techniques described below, and a decision on implantable cardioverter-defibrillator (ICD) implantation should be made accordingly.

Signal-averaged ECG

Arrhythmogenic right ventricular cardiomyopathy (ARVC) and Brugada syndrome may be difficult to differentiate in some cases. Late potentials on signal-averaged ECG may reveal the fibrofatty degeneration of the right ventricle seen in ARVC.

Challenge with sodium channel blockers

In some patients, the intravenous administration of drugs that block sodium channels may unmask or modify the ECG pattern, aiding in diagnosis and/or risk stratification in some individuals. Infuse flecainide 2 mg/kg (maximum 150 mg) over 10 minutes, procainamide 10 mg/kg over 10 minutes, ajmaline 1 mg/kg over 5 minutes, or pilsicainide 1 mg/kg over 10 minutes. This challenge should be performed with continuous cardiac monitoring and in a setting equipped for resuscitation.

In patients with a normal baseline ECG, the results are positive when the drug generates a J wave with an absolute amplitude of 2 mm or more in leads V1, V2, and/or V3 with or without an RBBB. Administration of the drug should be stopped when the result is positive, when ventricular arrhythmia occurs, or when QRS widening of greater than 30% is observed.

Isoproterenol and sodium lactate may be effective as antidotes if the sodium channel blocker induces an arrhythmia, and the isoproterenol response may also have diagnostic use.

This drug test should not be performed in patients with a type 1 ECG pattern (see Table above) because it adds no new information.

In patients with the type 2 or 3 patterns, the drug challenge is recommended to clarify the diagnosis.[13] The sensitivity and specificity of drug challenge testing is not yet confirmed. A 2012 study examining patients with type 2 or 3 patterns showed that a positive drug challenge in symptomatic patients was associated with adverse events. However, asymptomatic patients with a similar result had a low event rate. This study suggests that a drug challenge may aid in risk stratification for symptomatic patients with a nondiagnostic ECG, but may not be justified in asymptomatic patients.[29]

Electrophysiologic Study

Some investigators use an electrophysiologic study (EPS) to determine the inducibility of arrhythmias, in an effort to risk-stratify patients with Brugada syndrome. However, the predictive value of this approach is debated. In 2001, Brugada showed that inducibility may be a good predictor of outcome.[30] However, in 2002, Priori reported a poor predictive value of invasive testing.[31] A subsequent study by Gehi concluded that EPS was not of use in guiding the management of patients with Brugada syndrome.[32]

More recently, investigators independently examining a large series of patients from Europe and Japan have failed to find any predictive value for EPS. In the large registry of Brugada syndrome patients from Europe, only symptoms and a spontaneous type 1 Brugada ECG pattern, but not EPS, were predictive of arrhythmic events.[33] . In the smaller Japanese registry, only family history of sudden cardiac death at younger than 45 years and inferolateral early repolarization pattern on ECG predicted cardiac events.[28]

A study by Priori et al enrolled 308 patients with no history of cardiac arrest and a spontaneous or drug-induced type I ECG pattern.[34] Seventy eight of the patients had an ICD implanted prophylactically. EPS with a consistent stimulation protocol was performed on all patients; at a mean follow-up of 34 months, no differences were found in the incidence of appropriate ICD shocks or cardiac arrest between patients who were inducible and patients who were noninducible. Significant predictors of arrhythmia in this study included syncope and a spontaneous type I ECG pattern, a ventricular effective refractory period of less than 200 ms on EPS, and a fragmented QRS in the anterior precordial ECG leads.

Investigators from the United Kingdom examined a group of probands who suffered sudden arrhythmic death believed to be due to Brugada syndrome.[35] A retrospective review of risk factors determined that these patients would not have been considered high risk, calling into question the sensitivity of current risk factors (eg, symptoms, type I ECG pattern). However, few ECGs were available for examination in the probands with sudden death .

Placement of Implantable Cardioverter-Defibrillator

At present, implantation of an automatic implantable cardioverter-defibrillator (ICD) is the only treatment proved effective in treating ventricular tachycardia and fibrillation and preventing sudden death[13] in patients with Brugada syndrome. No pharmacologic therapy has been proved to reduce the occurrence of ventricular arrhythmias or sudden death.

Indications for ICD implantation were published in the report of the Second Consensus Conference on Brugada syndrome.[22]  For patients at the two extremes of risk stratification, the decision to implant or not to implant an ICD is relatively straightforward.

Patients with Brugada syndrome and a history of cardiac arrest must be treated with an ICD. In contrast, asymptomatic patients with no family history of sudden cardiac death can be managed conservatively with close follow-up, and ICD implantation is not recommended. Patients with intermediate clinical characteristics present the greatest challenge. For details about risk stratification and indications for ICD implantation, readers are referred to the Second Consensus Conference report.[22]

Patients with syncope or cardiac arrest and suspected or diagnosed Brugada syndrome must be hospitalized. Continuous cardiac monitoring is necessary until definitive treatment (ie, ICD placement) can be provided.

Activity

Because regular physical activity may increase vagal tone, sport may eventually enhance the propensity of athletes with Brugada syndrome to have ventricular fibrillation and sudden cardiac death at rest or during recovery after exercise. Accordingly, Pelliccia et al recommended that patients with a definite diagnosis of Brugada syndrome be restricted from participation competitive sports.[36]  However, no direct evidence supported this recommendation, and it was unclear whether asymptomatic carriers of SCN5A mutations should also be so restricted.

A scientific statement published in 2015 by the American Heart Association and the American College of Cardiology on athletic competition by persons with known or suspected cardiac channelopathies included the following recommendations related to Brugada syndrome[37] :

Consultations

A board-certified cardiologist who specializes in cardiac arrhythmic disorders (ie, a clinical electrophysiologist) should evaluate patients with suspected Brugada syndrome. Consultation with a genetic counselor is indicated for genetic screening and counseling of patients and their relatives.

Long-Term Monitoring

A board-certified electrophysiologist should closely follow patients with Brugada syndrome. Taking a careful history is important, as not all syncope is necessarily arrhythmic in Brugada syndrome. For example, a clear prodrome suggesting vasovagal syncope does not suggest an adverse prognosis in an otherwise asymptomatic patient with a Brugada ECG pattern.

Guidelines Summary

Diagnosis

In its 2013 expert consensus statement on inherited primary arrhythmia syndromes, the Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society (HRS/EHRA/APHRS) recommended a diagnosis of  Brugada syndrome (BrS) when the following criteria are met[38] :

In 2015, the European Society of Cardiology (ESC) released guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death (SCD) thatincluded the following specific recommendation for diagnosis of BrS.[39]

Class I (Level of evidence: C)

Brugada syndrome is diagnosed in patients with ST-segment elevation with type 1 morphology ≥2 mm in one or more leads among the right precordial leads V1 and/or V2 positioned in the second, third, or fourth intercostal space, occurring either spontaneously or after provocative drug test with intravenous administration of sodium channel blockers (such as ajmaline, flecainide, procainamide or pilsicainide).

Genetic testing

In 2011, the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA) issued a joint expert consensus statement on genetic testing for channelopathies and cardiomyopathies with the following recommendations for BrS testing[40] :

Management and prevention of sudden cardiac death

The following is a summary of recommendation included in the 2015 ESC guidelines for management of of LQTS and preventions of SCD.[39]

Class I  (Level of evidence: C)

Lifestyle changes:

ICD implantation in patients who are survivors of an aborted cardiac arrest and/or have documented spontaneous sustained ventricular tachycardia (VT).

Class IIa (Level of evidence: C)

Consider ICD in patients with a spontaneous diagnostic type I ECG pattern and history of syncope.

Consider quinidine or isoproterenol to treat electrical storms.

Consider quinidine for patients who qualify for an ICD but present a contraindication or refuse it and in patients who require treatment for supraventricular arrhythmias.

Class IIb (Level of evidence: C)

Consider ICD in patients who develop ventricular fibrillation during programmed ventricular stimulation with two or three extra stimuli at two sites.

Consider catheter ablation in patients with a history of electrical storms or repeated appropriate ICD shocks.

The 2013 HRS/EHRA/APHRS guidelines offer consistent recommendations. In additiona, the guidelines find ICD implantation is not indicated in asymptomatic BrS patients with a drug-induced type I ECG and on the basis of a family history of sudden cardiac death (SCD) alone.[38]

A scientific statement published in 2015 by the American Heart Association and the American College of Cardiology on athletic competition by persons with known or suspected cardiac channelopathies includes the following recommendations related to BrS[37] :

Medication Summary

Theoretically, drugs that counteract the ionic current imbalance in Brugada syndrome could be used to treat it. For example, quinidine, which blocks the calcium-independent transient outward potassium current (Ito), has been shown to normalize the ECG pattern in patients with Brugada syndrome.[3] However, quinidine also blocks sodium (Na) currents, which could have contrary effects.

Tedisamil, a potent Ito blocker without strong Na channel effects, may be more effective than quinidine.[41] Isoproterenol, which boosts the L-type calcium current, can also counteract the ionic current imbalance.[41]

Thus far, no drug therapy for Brugada syndrome is recommended because clinical trials have failed to convincingly prove effectiveness.[22, 42, 43, 44] A number of medications can unmask the Brugada pattern on ECG and potentially exacerbate the clinical manifestations of Brugada syndrome. The Web site BrugadaDrugs.org has been established to educate patients and professionals about these potentially dangerous medications.[45]

Quinidine

Clinical Context:  Quinidine maintains a normal heart rhythm following cardioversion of atrial fibrillation or flutter. It depresses myocardial excitability and conduction velocity. Prior to administration, control the ventricular rate and CHF (if present) with digoxin or calcium channel blockers.

Class Summary

There is general consensus that certain drugs can be potentially antiarrhythmic in Brugada syndrome patients. However, there are no randomized clinical studies in Brugada syndrome patients. As such, only in the setting of long-term therapeutic treatment in an experienced medical center can practitioners consider the use of antiarrhythmics for high-risk patients. Currently, quinidine seems to be the treatment of choice for long-term therapy.

What is Brugada syndrome (BrS)?What are the signs and symptoms of Brugada syndrome (BrS)?What is the significance of the lack of prodrome in Brugada syndrome (BrS)?How is Brugada syndrome (BrS) diagnosed?Which studies are used to diagnose Brugada syndrome (BrS)?What is the role of lab testing in the diagnosis of Brugada syndrome (BrS)?What is the role of echocardiography in the diagnosis of Brugada syndrome (BrS)?What is the role of an automatic implantable cardiac defibrillator (ICD).in the treatment of Brugada syndrome (BrS)?What is the role of pharmacologic therapy in the treatment of Brugada syndrome (BrS)?What is Brugada syndrome (BrS)?How is the heart affected in Brugada syndrome (BrS)?What is the role of genetics in the etiology of Brugada syndrome (BrS)?What are the clinical manifestations of Brugada syndrome (BrS)?How is ventricular tachycardia managed in Brugada syndrome (BrS)?What is the pathophysiology of Brugada syndrome (BrS)?What is the repolarization-defect therapy of the pathogenesis of Brugada syndrome (BrS)?Which readings on electrocardiogram (ECG) are characteristic of Brugada syndrome (BrS)?What is depolarization/conduction disorder model of Brugada syndrome (BrS)?What is the role of ajmaline provocation in the pathogenesis of Brugada syndrome (BrS)?What is the role of genetics in Brugada syndrome (BrS)?Which clinical situations may unmask or exacerbate the electrocardiogram (ECG) pattern of Brugada syndrome (BrS)?What is the prevalence of Brugada syndrome (BrS) in the US?What is the global prevalence of Brugada syndrome (BrS)?What are the racial predilections for Brugada syndrome (BrS)?How does the prevalence of Brugada syndrome (BrS) vary by sex?How does the prevalence of Brugada syndrome (BrS) vary by age?What is the prognosis of Brugada syndrome (BrS)?What are the risk factors for sudden cardiac death in patients with Brugada syndrome (BrS)?What is the incidence of cardiac death in patients with Brugada syndrome (BrS)?What is included in the patient education information for Brugada syndrome (BrS)?What are the signs and symptoms of Brugada syndrome (BrS)?What is a common finding in the history of patients with Brugada syndrome (BrS)?When do most cardiac events of Brugada syndrome (BrS) occur?What is the significance of a lack of prodrome in Brugada syndrome (BrS)?What is the purpose of physical exam in the evaluation of Brugada syndrome (BrS)?What is included in the differential diagnoses of cardiac arrest in Brugada syndrome (BrS)?What is included in differential diagnoses of right precordial ST-segment elevation in Brugada syndrome (BrS)?What are the differential diagnoses for Brugada Syndrome?How should syncope be evaluated in suspected Brugada syndrome (BrS)?Which lab studies are performed for the diagnosis of Brugada syndrome (BrS)?What is the role of genetic testing in the diagnosis of Brugada syndrome (BrS)?What is the role of echocardiography and/or MRI in the diagnosis of Brugada syndrome (BrS)?Which electrocardiogram (ECG) patterns have been described in Brugada syndrome (BrS)?What does the QRS duration on the 12-lead electrocardiogram (ECG) suggest in the evaluation of Brugada syndrome (BrS)?When should an electrophysiologist be consulted in the diagnosis of Brugada syndrome (BrS)?How are arrhythmogenic right ventricular cardiomyopathy (ARVC) and Brugada syndrome (BrS) differentiated?What is the role of sodium channel blockers in the workup of Brugada syndrome (BrS)?What is the purpose of an electrophysiologic study (EPS) in the diagnosis of Brugada syndrome (BrS)?What is the efficacy of electrophysiologic study (EPS) for the diagnosis of Brugada syndrome (BrS)?What are the treatment options for Brugada syndrome (BrS)?What are the indications for implantable cardioverter-defibrillator (ICD) implantation in the treatment of Brugada syndrome (BrS)?What are the treatment options for asymptomatic Brugada syndrome (BrS)?When is hospitalization indicated for the treatment of Brugada syndrome (BrS)?What are the activity restrictions for patients with Brugada syndrome (BrS)?What are the AHA/ACC activity recommendations for patients with Brugada syndrome (BrS)?Which specialists should be consulted in the diagnosis and management of Brugada syndrome (BrS)?What is included in the long-term monitoring of patients with Brugada syndrome (BrS)?What are the HRS/EHRA/ARHRS diagnostic criteria for Brugada syndrome (BrS)?Which organization released treatment guidelines for ventricular arrhythmias and the prevention of sudden cardiac death (SCD) in patients with Brugada syndrome (BrS)?What is the ESC diagnostic criteria for Brugada syndrome (BrS)?What are the HRS/EHRA guidelines for genetic testing in Brugada syndrome (BrS)?What are the ESC recommendations for lifestyle changes to manage Brugada syndrome (BrS) and prevent sudden cardiac death?What are the ESC guidelines class IIa level recommendations for the treatment of Brugada syndrome (BrS)?What are the ESC guidelines class IIb level recommendations for the treatment of Brugada syndrome (BrS)?What are the AHA/ACC guidelines for athletic competition for patients with Brugada syndrome (BrS)?Which medications are used in the treatment of Brugada syndrome (BrS)?Which medications in the drug class Antiarrhythmic Drugs are used in the treatment of Brugada Syndrome?

Author

Jose M Dizon, MD, Associate Professor of Clinical Medicine, Clinical Electrophysiology Laboratory, Division of Cardiology, Columbia University College of Physicians and Surgeons; Assistant Attending Physician, Department of Medicine, C\New York-Presbyterian/Columbia University Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

Tamim M Nazif, MD, Fellow, Division of Cardiology, Columbia University College of Physicians and Surgeons

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ronald J Oudiz, MD, FACP, FACC, FCCP, Professor of Medicine, University of California, Los Angeles, David Geffen School of Medicine; Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, LA Biomedical Research Institute at Harbor-UCLA Medical Center

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Actelion, Bayer, Gilead, Lung Biotechnology, United Therapeutics<br/>Received research grant from: Actelion, Bayer, Gilead, Ikaria, Lung Biotechnology, Pfizer, Reata, United Therapeutics<br/>Received income in an amount equal to or greater than $250 from: Actelion, Bayer, Gilead, Lung Biotechnology, Medtronic, Reata, United Therapeutics.

Chief Editor

Mikhael F El-Chami, MD, Associate Professor, Department of Medicine, Division of Cardiology, Section of Electrophysiology, Emory University School of Medicine

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Medtronic; Boston Scientific<br/>Received grant/research funds from Medtronic Inc for principle investigator.

Additional Contributors

Justin D Pearlman, MD, ME, PhD, FACC, MA, Chief, Division of Cardiology, Director of Cardiology Consultative Service, Director of Cardiology Clinic Service, Director of Cardiology Non-Invasive Laboratory, Chair of Institutional Review Board, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

References

  1. Bordachar P, Reuter S, Garrigue S, et al. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J. 2004 May. 25(10):879-84. [View Abstract]
  2. Take Y, Morita H, Toh N, Nishii N, Nagase S, Nakamura K, et al. Identification of high-risk syncope related to ventricular fibrillation in patients with Brugada syndrome. Heart Rhythm. 2012 May. 9(5):752-9. [View Abstract]
  3. Antzelevitch C, Brugada P, Brugada J, Brugada R, Nademanee K, Towbin J. The Brugada syndrome. Clinical approaches to tachyarrhythmias. Armonk NY: Futura Publishing Company; 1999.
  4. Frustaci A, Priori SG, Pieroni M, Chimenti C, Napolitano C, Rivolta I, et al. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation. 2005 Dec 13. 112(24):3680-7. [View Abstract]
  5. Martini B, Nava A, Thiene G, Buja GF, Canciani B, Scognamiglio R, et al. Ventricular fibrillation without apparent heart disease: description of six cases. Am Heart J. 1989 Dec. 118(6):1203-9. [View Abstract]
  6. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation. 2003 Dec 23. 108(25):3092-6. [View Abstract]
  7. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992 Nov 15. 20(6):1391-6. [View Abstract]
  8. Vorobiof G, Kroening D, Hall B, Brugada R, Huang D. Brugada syndrome with marked conduction disease: dual implications of a SCN5A mutation. Pacing Clin Electrophysiol. 2008 May. 31(5):630-4. [View Abstract]
  9. Kusano KF, Taniyama M, Nakamura K, Miura D, Banba K, Nagase S, et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol. 2008 Mar 25. 51(12):1169-75. [View Abstract]
  10. Alings M, Wilde A. "Brugada" syndrome: clinical data and suggested pathophysiological mechanism. Circulation. 1999 Feb 9. 99(5):666-73. [View Abstract]
  11. Meregalli PG, Wilde AA, Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more?. Cardiovasc Res. 2005 Aug 15. 67(3):367-78. [View Abstract]
  12. Nagase S, Kusano KF, Morita H, Nishii N, Banba K, Watanabe A, et al. Longer repolarization in the epicardium at the right ventricular outflow tract causes type 1 electrocardiogram in patients with Brugada syndrome. J Am Coll Cardiol. 2008 Mar 25. 51(12):1154-61. [View Abstract]
  13. Antzelevitch C, Brugada P, Brugada J, Brugada R. Brugada syndrome: from cell to bedside. Curr Probl Cardiol. 2005 Jan. 30(1):9-54. [View Abstract]
  14. Postema PG, van Dessel PF, Kors JA, Linnenbank AC, van Herpen G, Ritsema van Eck HJ, et al. Local depolarization abnormalities are the dominant pathophysiologic mechanism for type 1 electrocardiogram in brugada syndrome a study of electrocardiograms, vectorcardiograms, and body surface potential maps during ajmaline provocation. J Am Coll Cardiol. 2010 Feb 23. 55(8):789-97. [View Abstract]
  15. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010 Jan. 7(1):33-46. [View Abstract]
  16. Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007 Jan 30. 115(4):442-9. [View Abstract]
  17. London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S, et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation. 2007 Nov 13. 116(20):2260-8. [View Abstract]
  18. Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ, et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest. 2008 Jun. 118(6):2260-8. [View Abstract]
  19. Donohue D, Tehrani F, Jamehdor R, Lam C, Movahed MR. The prevalence of Brugada ECG in adult patients in a large university hospital in the western United States. Am Heart Hosp J. 2008 Winter. 6(1):48-50. [View Abstract]
  20. Nademanee K, Veerakul G, Nimmannit S, Chaowakul V, Bhuripanyo K, Likittanasombat K, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation. 1997 Oct 21. 96(8):2595-600. [View Abstract]
  21. Bezzina CR, Shimizu W, Yang P, Koopmann TT, Tanck MW, Miyamoto Y, et al. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation. 2006 Jan 24. 113(3):338-44. [View Abstract]
  22. [Guideline] Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005 Feb 8. 111(5):659-70. [View Abstract]
  23. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation. 2002 Nov 5. 106(19):2514-9. [View Abstract]
  24. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, Sitthisook S, Tosukhowong P, Tungsanga K. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J. 2001 Dec. 22(24):2290-6. [View Abstract]
  25. Takagi M, Yokoyama Y, Aonuma K, Aihara N, Hiraoka M. Clinical characteristics and risk stratification in symptomatic and asymptomatic patients with brugada syndrome: multicenter study in Japan. J Cardiovasc Electrophysiol. 2007 Dec. 18(12):1244-51. [View Abstract]
  26. Junttila MJ, Brugada P, Hong K, Lizotte E, DE Zutter M, Sarkozy A, et al. Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol. 2008 Apr. 19(4):380-3. [View Abstract]
  27. Sarkozy A, Chierchia GB, Paparella G, Boussy T, De Asmundis C, Roos M, et al. Inferior and lateral electrocardiographic repolarization abnormalities in Brugada syndrome. Circ Arrhythm Electrophysiol. 2009 Apr. 2(2):154-61. [View Abstract]
  28. Kamakura S, Ohe T, Nakazawa K, Aizawa Y, Shimizu A, Horie M, et al. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3. Circ Arrhythm Electrophysiol. 2009 Oct. 2(5):495-503. [View Abstract]
  29. Zorzi A, Migliore F, Marras E, Marinelli A, Baritussio A, Allocca G, et al. Should all individuals with a nondiagnostic Brugada-electrocardiogram undergo sodium-channel blocker test?. Heart Rhythm. 2012 Jun. 9(6):909-16. [View Abstract]
  30. Brugada P, Geelen P, Brugada R, Mont L, Brugada J. Prognostic value of electrophysiologic investigations in Brugada syndrome. J Cardiovasc Electrophysiol. 2001 Sep. 12(9):1004-7. [View Abstract]
  31. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002 Mar 19. 105(11):1342-7. [View Abstract]
  32. Gehi AK, Duong TD, Metz LD, Gomes JA, Mehta D. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol. 2006 Jun. 17(6):577-83. [View Abstract]
  33. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation. 2010 Feb 9. 121(5):635-43. [View Abstract]
  34. Priori SG, Gasparini M, Napolitano C, et al. Risk Stratification in Brugada Syndrome Results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) Registry. J Am Coll Cardiol. 2012 Jan 3. 59(1):37-45. [View Abstract]
  35. Raju H, Papadakis M, Govindan M, et al. Low prevalence of risk markers in cases of sudden death due to brugada syndrome relevance to risk stratification in brugada syndrome. J Am Coll Cardiol. 2011 Jun 7. 57(23):2340-5. [View Abstract]
  36. Pelliccia A, Fagard R, Bjørnstad HH, Anastassakis A, Arbustini E, Assanelli D, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005 Jul. 26(14):1422-45. [View Abstract]
  37. [Guideline] Ackerman MJ, Zipes DP, Kovacs RJ, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2015 Dec 1. 132 (22):e326-9. [View Abstract]
  38. [Guideline] Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 Dec. 10 (12):1932-63. [View Abstract]
  39. [Guideline] Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015 Nov 1. 36 (41):2793-867. [View Abstract]
  40. [Guideline] Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011 Aug. 13 (8):1077-109. [View Abstract]
  41. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol. 2001 Feb. 12(2):268-72. [View Abstract]
  42. Márquez MF, Salica G, Hermosillo AG, Pastelín G, Gómez-Flores J, Nava S, et al. Ionic basis of pharmacological therapy in Brugada syndrome. J Cardiovasc Electrophysiol. 2007 Feb. 18(2):234-40. [View Abstract]
  43. Márquez MF, Salica G, Hermosillo AG, Pastelín G, Cárdenas M. Drug therapy in Brugada syndrome. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Oct. 5(5):409-17. [View Abstract]
  44. Yang F, Hanon S, Lam P, Schweitzer P. Quinidine revisited. Am J Med. 2009 Apr. 122(4):317-21. [View Abstract]
  45. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009 Sep. 6(9):1335-41. [View Abstract]

Three types of ST-segment elevation in Brugada syndrome, as shown in the precordial leads on ECG in the same patient at different times. Left panel shows a type 1 ECG pattern with pronounced elevation of the J point (arrow), a coved-type ST segment, and an inverted T wave in V1 and V2. The middle panel illustrates a type 2 pattern with a saddleback ST-segment elevated by >1 mm. The right panel shows a type 3 pattern in which the ST segment is elevated &lt; 1 mm. According to a consensus report (Antzelevitch, 2005), the type 1 ECG pattern is diagnostic of Brugada syndrome. Modified from Wilde, 2002. Image courtesy of Richard Nunez, MD, and EMedHome.com (http://www.emedhome.com/).

Three types of ST-segment elevation in Brugada syndrome, as shown in the precordial leads on ECG in the same patient at different times. Left panel shows a type 1 ECG pattern with pronounced elevation of the J point (arrow), a coved-type ST segment, and an inverted T wave in V1 and V2. The middle panel illustrates a type 2 pattern with a saddleback ST-segment elevated by >1 mm. The right panel shows a type 3 pattern in which the ST segment is elevated &lt; 1 mm. According to a consensus report (Antzelevitch, 2005), the type 1 ECG pattern is diagnostic of Brugada syndrome. Modified from Wilde, 2002. Image courtesy of Richard Nunez, MD, and EMedHome.com (http://www.emedhome.com/).

Schematics show the 3 types of action potentials in the right ventricle: endocardial (End), mid myocardial (M), and epicardial (Epi). A, Normal situation on V2 ECG generated by transmural voltage gradients during the depolarization and repolarization phases of the action potential. B-E, Different alterations of the epicardial action potential that produce the ECG changes observed in patients with Brugada syndrome. Adapted from Antzelevitch, 2005.

Three types of ST-segment elevation in Brugada syndrome, as shown in the precordial leads on ECG in the same patient at different times. Left panel shows a type 1 ECG pattern with pronounced elevation of the J point (arrow), a coved-type ST segment, and an inverted T wave in V1 and V2. The middle panel illustrates a type 2 pattern with a saddleback ST-segment elevated by >1 mm. The right panel shows a type 3 pattern in which the ST segment is elevated &lt; 1 mm. According to a consensus report (Antzelevitch, 2005), the type 1 ECG pattern is diagnostic of Brugada syndrome. Modified from Wilde, 2002. Image courtesy of Richard Nunez, MD, and EMedHome.com (http://www.emedhome.com/).

Schematics show the 3 types of action potentials in the right ventricle: endocardial (End), mid myocardial (M), and epicardial (Epi). A, Normal situation on V2 ECG generated by transmural voltage gradients during the depolarization and repolarization phases of the action potential. B-E, Different alterations of the epicardial action potential that produce the ECG changes observed in patients with Brugada syndrome. Adapted from Antzelevitch, 2005.

Three types of ST-segment elevation in Brugada syndrome, as shown in the precordial leads on ECG in the same patient at different times. Left panel shows a type 1 ECG pattern with pronounced elevation of the J point (arrow), a coved-type ST segment, and an inverted T wave in V1 and V2. The middle panel illustrates a type 2 pattern with a saddleback ST-segment elevated by >1 mm. The right panel shows a type 3 pattern in which the ST segment is elevated &lt; 1 mm. According to a consensus report (Antzelevitch, 2005), the type 1 ECG pattern is diagnostic of Brugada syndrome. Modified from Wilde, 2002. Image courtesy of Richard Nunez, MD, and EMedHome.com (http://www.emedhome.com/).

Characteristic Type 1 Type 2 Type 3
J wave amplitude≥2 mm≥2 mm≥2 mm
T waveNegativePositive or biphasicPositive
ST-T configurationCove-typeSaddlebackSaddleback
ST segment, terminal portionGradually descendingElevated by ≥1 mmElevated by < 1 mm